| abstract |
The present invention relates to a new use of erythromycin lignans. Specifically, the present invention provides the use of erythropoietin (compound shown in formula I) to prepare a pharmaceutical composition or preparation for preventing and/or treating related diseases mediated by JAK/STAT and/or NF-κB signaling pathway. For the first time, the selective inhibition of JAK/STAT and NF-κB signaling pathway by erythropoietin was found, and it has the prospect of treating related diseases through JAK/STAT and/or NF-κB dual signaling pathway. |